The Department of Health and Human Services today issued a final rule making Jan. 1 the effective date of its final regulations on drug ceiling prices and civil monetary penalties for manufacturers under the 340B Drug Pricing Program. 

“The AHA is pleased that in response to our lawsuit, today’s final rule ensures that the implementation of the long-delayed 340B Drug Pricing Program ceiling price and civil monetary penalties policies will be effective Jan. 1, 2019,” AHA Executive Vice President Tom Nickels said in a statement. “Earlier this year, the AHA along with other national organizations representing 340B hospitals, filed a lawsuit to force implementation of this rule in order to shine needed light on drug pricing and to hold price-gouging drug companies accountable. We continue to strongly urge HHS to make available online drug pricing information for 340B hospitals as this rule requires as soon as possible after Jan. 1, and no later than April 1, so that instances of drug company overcharging can be uncovered and penalties enforced.”

The AHA, Association of American Medical Colleges, America's Essential Hospitals, 340B Health and three hospital systems in September filed the lawsuit. 
 

Headline
The AHA Oct. 27 submitted comments on the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B…
Headline
The U.S. District Court for the District of Maine should deny motions by several drug companies and Pharmaceutical Research and Manufacturers of America to…
Headline
The AHA today voiced support () for the 340B Rebate Model Delay Act (H.R. 10770)in a letter to the bill’s House sponsors. The bipartisan bill would pause the…
Headline
The AHA, the Maine Hospital Association and four safety-net hospitals Oct. 9 filed a lawsuit in the U.S. District Court for the District of Maine challenging…
Headline
The AHA, the New Hampshire Hospital Association and 340B Health have filed an amicus brief supporting Mary Hitchcock Memorial Hospital’s request for a…
Headline
The Department of Health and Human Services’ Health Resources and Services Administration Oct. 1 announced approval of 10 drug companies to participate in the…